ImmunomedicsStock Price and Value Analysis

Should you buy Immunomedics stock? (NasdaqGM:IMMU). Let's see how it does in our automated value investing analysis system.

  • This company is solid.
  • This company is not making money.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company pays no dividend.

IMMU Free Cash Flow Trend

Hmm, we can't give any reliable projection for Immunomedics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for IMMU
Free Cash Flow trendline for Immunomedics

Inside the IMMU Numbers

IMMU Price
(Immunomedics stock price per share)
[?] PE Ratio versus Sector 1474% higher than other Healthcare stocks
[?] PE Ratio versus Industry 451% higher than other Biotechnology stocks
[?] Cash Yield -1.96%
[?] Free Cash Flow Jitter 117%

Is Immunomedics Stock on Sale?

Based on our analysis, we believe that you should not buy Immunomedics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy IMMU Stock?

Does Immunomedics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.